R-TUM 1gm. - Ceftazidime for Inj. I.P.

Composition Each vial contains: Ceftazidime for Inj. I.P. Product Description Ceftazidime is a third-generation cephalosporin antibiotic. Mechanism of Action it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections. Pharmaco Kinetics Bioavailability - 91% (IM) ; Metabolism - negligible ; Half life - 1.6–2 hours ; Excretion - 90–96% renal. Indications Ceftazidime is usually reserved for the treatment of infections caused by Pseudomonas aeruginosa. It is also used in the empirical therapy of febrile neutropenia, in combination with other antibiotics.

Dosage The usual dose is 1–2 g IV/IM every 8–12 hours(2 - 3times), though this can vary by the indication, infection severity, and/or renal function of the recipient. Contra Indication Special Precautions he total daily dosage should be reduced when ceftazidime is administered to patients with renal insufficiency Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics. Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials. Adverse Effects Phlebitis and inflammation at the site of injection (1 in 69 patients); pruritus, rash, and fever in 2% ; diarrhea (1 in 78), nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). Packing A vial of 250 mg.